CBER Proposes Increasing Cell, Gene Therapy Staff In PDUFA VII
Executive Summary
'Indirect and direct review roles' would be added with user fee funds after the PDUFA program is reauthorized.
You may also be interested in...
PDUFA VII Could Expand US Real-Time Review Beyond Oncology
A proposed pilot program would offer for “split submission and review” of some application sections in other disease areas. Discussions also touch on concept of a CDER-CBER RWE committee.
PDUFA Renewal Negotiations Nearly Complete, With CBER Slated For Major Resource Increase
While the prescription drug user fee agreement between industry and the US FDA is almost done, generic renewal talks remain ongoing, and biosimilar talks have not started.
US FDA Could Be Facing Bolus Of Pandemic-Related Applications
Acting CDER Director Cavazzoni says it is ‘a very active time’ as many clinical trials for COVID-19-related products are expected to read out soon.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: